Detail Data
Volume (24h): 52,769 shares
P/E Ratio: /
Forward P/E: /
EPS: -0.61 EUR
Forward EPS: /
Number of Shares: 92,157,200 shares
Market Capitalization: 184,775,200.00 EUR

Dividend

Dividend Value
Dividend Amount According to our data, the company Innate Pharma does not currently pay dividends.
Annual Yield %: -
Ex-dividend Date: -
5-Year Avg Yield %: -
Payout Ratio: -
Last Dividend Value: -
Last Dividend Date: -

Analyst Forecast

Most analysts have issued a none recommendation for Innate Pharma stock. The current number of analysts covering this company is 5. The highest target price is 8.4 EUR, while the lowest target price is 2.43 EUR. The median target valuation set by analysts is 6.2 EUR. These forecasts and recommendations provide insight into how analysts view the future stock performance of Innate Pharma.
Analysts Recommendation
Issued Recommendation: According to our data, the recommendation for Innate Pharma stock is: none
Number of Analysts: 5
Highest Target Price: 8.4 EUR
Lowest Target Price: 2.43 EUR
Median Target Price: 6.2 EUR

Fundamental Indicators

Indicator Data
Total Revenue: 20,121,000.00 EUR
Net Income: -49,471,000.00 EUR
Price-to-Book (P/B): 19.10
PEG Ratio: /
Exchange: Paris
Industry: Biotechnology
Sector: Healthcare
Number of Employees: 181
Country: France

Where to Buy Innate Pharma Stock?

You can purchase Innate Pharma stock on the Paris under the ticker symbol: IPH.PA. Several stock brokers or banks offer trading services for these stocks. Popular stock brokers like XTB and eToro allow you to buy real stocks and ETFs with zero or minimal commissions. Banks usually charge higher fees. Remember, investing in stocks involves risks, so it's important to carefully consider your financial situation and investment goals.

1

Real stocks and ETFs. Low minimum deposit, only 50 EUR. Option to copy trades. Advanced stock analysis and free education.

Trustpilot rating 4.4/5 Google play rating 4.2/5
Invest in Stocks with eToro
★★★★★ 5.0
2

Real stocks and ETFs + free demo account. Low fees + fast customer support. More than 5,200 instruments available for trading. Free training and education. Regular live streams on YouTube.

Trustpilot rating 3.6/5 Google play rating 4.5/5
Try Free Demo Account
★★★★☆ 4.8
Risk warning: Trading CFDs involves a high risk of financial loss. Between 51%-eToro -89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

More Information on Innate Pharma Stock

Indicator Value
Company Revenue: 20,121,000.00 EUR
EBITDA: -50,274,000.00 EUR - Negative EBITDA may signal financial challenges or growth investments.
Earnings Per Share: -0.61 EUR
Book Value Per Share: 0.11 EUR
Total Cash: 80,770,000.00 EUR
Total Cash per Share: 0.88 EUR
Total Debt: 30,995,000.00 EUR
Debt to Equity Ratio: 3.51
Quick Ratio 2.50
Current Ratio 2.60
Free Cash Flow 17,116,876.00 EUR
Operating Cash Flow -6,896,000.00 EUR
Gross Margins -158.34 %
EBITDA Margins -249.86 %
Operating Margins -324.87 %
Profit Margins -245.87 %
Return on Assets -22.5 %
Return on Equity -162.9 %
Earnings Growth (1 year) -
Revenue Growth (1 year) -63.7 %
Quarterly Earnings Year-over-Year Growth -
Market Capitalization 184,775,200.00 EUR
Enterprise Value 138,686,368.00 EUR
EV/Revenue 6.893
EV/EBITDA -2.759
Float Shares 34,421,616 shares
Shares Outstanding 92,157,200 shares
Held Percent Insiders 0.31 %
Held Percent Institutions 10.17 %
Shares Short -
Shares Short Prior Month -
Date Short Interest -
Short Percentage of Total Shares -
Short Ratio -
Beta 0.94
Short Percentage of Float -
Implied Shares Outstanding 92,636,096

Frequently Asked Questions (FAQ)

According to our data, the company Innate Pharma does not pay dividends yet, even in 2025.

Innate Pharma shares are traded on the Paris stock exchange under the ticker: IPH.PA. You can buy or trade them through a variety of stock brokers who provide real stock trading services.

According to our data, the recommendation for Innate Pharma shares is from a total of 5 analysts. The average target price prediction is 6.2 EUR per share.

The total number of Innate Pharma shares on the exchange is 92,157,200.00 shares, which at the current market capitalization gives the company a total valuation of 184,775,200.00 EUR.